AMSBIO announces the launch of the Oris 3D Embedded Invasion Assay – a unique product offering quantifiable real-time analysis of cell invasion
The invasion capacity of tumor cells is of particular concern in cancer research, and is a first step to metastasis, the deadliest aspect of the disease. Traditionally, cell invasion assays are performed by seeding cells in a chamber and assessing invasion by counting cells that penetrate through a flat, two dimensional ECM, typically a coated porous membrane, towards a lower chamber. However, these membranes are unlike any in vivo structure, potentially compromising the physiological relevance of the assay. Moreover, traditional invasion assays are not amendable to real-time monitoring, as cells can only be viewed microscopically post-invasion through the membrane, precluding real-time analysis of changes in invasion rate and cell morphology.
Based upon patented “exclusion zone” technology which uses cells embedded in a collagen matrix – Oris™ 3D Embedded Invasion Assays from AMSBIO provide a simple, quantitative, and efficient way to monitor cell invasion and morphology changes in a more physiologically relevant microenvironment. With no artificial membranes obscuring visualization of the cells, cell invasion rates and morphology changes can be reproducibly and quantifiably measured as end-point assays or in real-time. Designed in an industry-standard 96-well plate format, the assay can be used with microscopes, plate readers and high content imaging system thereby delivering significant reductions in handling time for set up and analysis.